<DOC>
	<DOCNO>NCT01554020</DOCNO>
	<brief_summary>This prospective international clinical trial two-arm , double-blind , randomize , placebo-controlled , parallel-group , multicenter study . 112 prediabetic subject randomize Blood Sugar Take Care placebo . Randomization stratify gender . The intervention period 12 week . The primary outcome fast glucose level .</brief_summary>
	<brief_title>Blood Sugar Take Care Glucose Metabolism</brief_title>
	<detailed_description />
	<mesh_term>Prediabetic State</mesh_term>
	<criteria>SUBJECT INCLUSION CRITERIA : STEP 1 1 . Age ≥ 18 year 2 . Subject meet American Diabetes Association criterion diabetes test asymptomatic , undiagnosed individual : 1 . If age ≥45 year , subject must body mass index ≥ 25 kg/m2 United States ≥ 24 kg/m2 Indonesia 2 . If age &lt; 45 year , subject must body mass index ≥ 25 kg/m2 United States ≥ 24 kg/m2 Indonesia AND present least one follow risk factor : Have firstdegree relative diabetes Habitually physically inactive Race AfricanAmerican , Hispanic American , Native American , Asian American , Pacific Islander Have deliver baby weigh &gt; 9 lb diagnose gestational diabetes mellitus Hypertensive ( ≥140/90 ) Known HDL cholesterol level 35 mg/dl Known triglyceride level ≥250 mg/dl On previous testing , impair glucose tolerance impair fast glucose History vascular disease 3 . Stable body weight ( &lt; 5 % change ) last 3 month 4 . Agree use contraception throughout study period , unless postmenopausal surgically sterile ( female ) 5 . Able understand nature purpose study include potential risk side effect 6 . Willing consent study participation comply study requirement SUBJECT EXCLUSION CRITERIA 1 . Known diabetes ( type I II ) 2 . Recent use ( within 2 week screen ) dietary supplement include vitamin mineral complex ; herbal supplement ; fish oil ; fiber supplement ; herbal ingredient/product significantly affect glucose lipid metabolism 3 . Recent use ( within 4 week screen ) prescription OTC medication significantly affect glucose lipid metabolism , include limited , sulfonylureas , meglitinides , biguanides , thiazolidinediones , alphaglucosidase inhibitor , DPP4 inhibitor , systemic corticosteroid , statin , fibrates , niacin , bile acid sequestrants 4 . Daily use nonsteroidal antiinflammatory drug ( NSAIDS ) ; ( daily baby aspirin use acceptable ) 5 . Any comorbidity could , opinion investigator , preclude subject 's ability successfully safely complete study may confound study outcomes 6 . Anticipated change dietary pattern physical activity level study , include attempt body weight reduction 7 . Eating disorder 8 . Polycystic ovary syndrome 9 . Known allergy substance study product 10 . Pregnant breastfeed woman 11 . History alcohol , drug , medication abuse 12 . Participation another study investigational product within 3 month screen 13 . Recent ( &lt; 3 month ) gastrointestinal surgery plan surgery treatment period SUBJECT INCLUSION CRITERIA : STEP 2 1 . Fasting glucose 95 130 mg/dl , base portable glucometer reading SUBJECT INCLUSION CRITERIA : STEP 3 1 . Impaired fast glucose , base American Diabetes Association definition fast serum glucose 100 125 mg/dl 2 . Impaired glucose tolerance , base American Diabetes Association definition serum glucose 140 199 mg/dl 2 hour 75 g glucose load</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Blood glucose</keyword>
	<keyword>Insulin sensitivity</keyword>
	<keyword>Oral glucose tolerance</keyword>
</DOC>